Molina Healthcare GLP-1 Coverage & Prior-Authorization Guide (2026)

For most Molina Healthcare members, GLP-1s for chronic weight management (Wegovy, Zepbound, Saxenda) are not covered — they are an explicit benefit exclusion in the many states that invoke the federal optional weight-loss-drug exclusion, and Molina Medicare Part D cannot cover them for weight loss by statute. Coverage exists only in a narrow set of markets (e.g., California and New Mexico Marketplace, and the ~13 Medicaid states that opt to cover obesity drugs), and only with prior authorization for “medically necessary treatment of morbid obesity.” Diabetes GLP-1s (Ozempic, Mounjaro) are covered under the diabetes benefit.

Bottom line: what Molina covers (and doesn't)

• Molina's own policy: in states where weight-loss drugs are a benefit exclusion, Wegovy is ‘considered a benefit exclusion for all indications, including but not limited to weight reduction and chronic weight management’ — the exclusion even extends to Wegovy's cardiovascular and MASH indications (policy C27682-A).
• The Zepbound policy (C29112-A) says Zepbound ‘is considered a benefit exclusion for all indications, including weight reduction to treat moderate to severe obstructive sleep apnea.’
• Both cite the federal basis: excluded ‘per Social Security 1927 (d)(3)(A)’ — the optional-exclusion list that lets states exclude agents used for weight loss.
• Coverage is state-specific and varies widely: Molina runs separate state plans; California and New Mexico Marketplace are flagged exceptions with their own criteria.
• Where covered (per Molina's California appendix), plans need only cover weight-loss drugs ‘when medically necessary for the treatment of morbid obesity,’ and may require enrollment in a comprehensive weight-loss program.
• Molina Medicare (Part D) is bound by the federal statutory weight-loss exclusion, so it does not cover Wegovy/Zepbound/Saxenda for chronic weight management (only a separately FDA-approved covered use like type 2 diabetes).
• Nationwide context (KFF, Jan 2026): only 13 state Medicaid programs cover GLP-1s for obesity under fee-for-service; several states (CA, NH, PA, SC) eliminated obesity coverage; NC dropped it Oct 2025 then reinstated by Dec 2025.

What Molina's policy says

In states where weight loss drugs are a benefit exclusion, Wegovy (semaglutide) injection and tablets are considered a benefit exclusion for all indications, including but not limited to weight reduction and chronic weight management, weight reduction to lower risk for repeat cardiovascular event in individuals with history of prior heart attack or stroke, metabolic dysfunction-associated steatohepatitis, and so on.

— Molina Healthcare Drug and Biologic Coverage Criteria — Wegovy, Policy C27682-A (molinamarketplace.com).

Wegovy (semaglutide) is excluded from coverage for overweight/obesity per Social Security 1927 (d)(3)(A).

— Molina Healthcare, Wegovy Policy C27682-A (molinamarketplace.com).

(3) When prescribed solely for the purposes of losing weight, except when medically necessary for the treatment of morbid obesity. Plans may require enrollees who are prescribed drugs for morbid obesity to be enrolled in a comprehensive weight loss program, if covered by the plan, for a reasonable period of time prior to or concurrent with receiving the prescription drug.

— Molina Wegovy policy C27682-A, California Marketplace appendix (California Title 28) (molinamarketplace.com).

Prior-authorization criteria (where covered)

• Where weight-loss GLP-1s are excluded (most Molina markets), the benefit exclusion cannot be overridden — Molina states exclusions ‘are not covered and cannot be approved for coverage by formulary exception.’
• In markets that do cover (CA/NM Marketplace and opt-in Medicaid states), coverage is limited to ‘medically necessary treatment of morbid obesity’ with prior authorization and full medical documentation.
• Molina's California appendix allows plans to require enrollment in a comprehensive weight-loss program before or concurrent with the drug.
• Typical eligibility mirrors the FDA label echoed in Molina's policy: obesity (BMI ≥ 30) or overweight (BMI ≥ 27) with a weight-related comorbidity.

How to appeal a Molina denial

• File an internal plan appeal after a denial — a member, provider, or authorized representative generally has 60 days from the notice, though each state's contract sets the exact window.
• Molina resolves a standard appeal within 30 calendar days (up to a 14-day extension); an expedited appeal within 72 hours.
• If the plan upholds the denial, the member may request a State Fair Hearing — federal rules allow at least 90 days from the plan's final decision.
• A grievance (a service or quality complaint) is a separate track from an appeal.
• An appeal cannot overturn a true benefit exclusion — if the state excludes weight-loss drugs, that exclusion is not appealable on medical-necessity grounds.

Molina runs dozens of state-specific plans and updates policies several times a year — always confirm the member's state plan and current Evidence of Coverage or Preferred Drug List. Verbatim quotes come from the SC-hosted Wegovy policy and UT-hosted Zepbound policy; state copies live at different URLs. Exact BMI thresholds and step-therapy details were not pulled verbatim from Molina's dedicated Weight Management policy, and the appeal day-counts are state-contract-dependent.

Further reading

• Cheapest GLP-1 without insurance: buyer's guide
• Best semaglutide providers